A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Pancreatic Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Biopsy-proven metastatic pancreatic adenocarcinoma (pancreatic cancer) 2) Subjects have received two (2) and not more than two (2) previous lines of therapy for the treatment of pancreatic cancer. 3) Radiographically measurable disease of at least one site by CT scan 4) Subjects must have completed any investigational cancer therapy at least 30 days prior to first dose. 5) Subjects must have completed any other cancer therapy at least 14 days prior to first dose and recovered from major side effects of prior therapies or procedures.

You may not be eligible for this study if the following are true:

  • 1) Any screening laboratory, ECG, or other findings that, in the opinion of the investigator, medical monitor or the sponsor, indicate an unacceptable risk for the subject’s participation in the study. 2) History or evidence of any clinically significant disorder, condition, or disease that, in the opinion of the investigator or medical monitor would pose a risk to the subject’s safety or interfere with the study evaluations, procedures, or completion. 3) History of a concurrent or second malignancy, except for adequately treated localized basal cell or squamous cell carcinoma of the skin, adequately treated superficial bladder cancer, adequately treated Stage 1 or 2 cancer currently in complete remission; or any other cancer that has been in complete remission for = 5 years.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.